D

Dynavax Technologies Corp
D

DVAX

10.265
USD
-0.14
(-1.35%)
مغلق
حجم التداول
45,348
الربح لكل سهم
0
العائد الربحي
-
P/E
-20
حجم السوق
1,232,627,872
أصول ذات صلة
A
AEMD
-0.17500
(-8.93%)
1.78500 USD
B
BCRX
-0.040
(-0.38%)
10.360 USD
H
HRTX
-0.08000
(-4.00%)
1.92000 USD
L
LPCN
0.02000
(0.64%)
3.13000 USD
M
MNKD
-0.11500
(-3.01%)
3.70500 USD
S
SNDX
-0.430
(-4.03%)
10.240 USD
المزيد
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.